Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2025

Nov 14, 2025

SELL
$366.54 - $479.53 $24,558 - $32,128
-67 Reduced 5.57%
1,135 $444,000
Q1 2025

May 15, 2025

BUY
$402.49 - $513.76 $272,485 - $347,815
677 Added 128.95%
1,202 $582,000
Q4 2024

Feb 13, 2025

BUY
$396.64 - $516.74 $208,236 - $271,288
525 New
525 $211,000

Others Institutions Holding VRTX

About VERTEX PHARMACEUTICALS INC


  • Ticker VRTX
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 256,691,008
  • Market Cap $111B
  • Description
  • Vertex Pharmaceuticals Incorporated, a biotechnology company, engages in developing and commercializing therapies for treating cystic fibrosis. The company markets SYMDEKO/SYMKEVI, ORKAMBI, and KALYDECO to treat patients with cystic fibrosis who have specific mutations in their cystic fibrosis transmembrane conductance regulator gene; and TRIKAF...
More about VRTX
Track This Portfolio

Track First Commonwealth Financial Corp Portfolio

Follow First Commonwealth Financial Corp and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of First Commonwealth Financial Corp , based on Form 13F filings with the SEC.

News

Stay updated on First Commonwealth Financial Corp with notifications on news.